Ezra announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence (AI), designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first Prostate AI to ever be cleared by the FDA.
[Ezra (PR Newswire, Inc.)]
6630899 nan items 1 apa default asc 1
The authors summarize the regulatory mode of post-translational modifications on KRAS. They also highlight the recent studies targeting these modifications having exhibited potent anti-tumor activities, including in prostate cancer.
[Acta Pharmacologica Sinica]
The authors present evidence that in the prostate cancer cell line DU145, the tubules arise in actively growing cells from vesicles in the medial and trans elements of a partially fragmented Golgi complex, while in not actively growing cells the tubules become completely independent from the Golgi complex.
[Experimental Cell Research]
6630899 3U8VXEG3 items 1 apa default asc 1
Nolfi, D., Capone, A., Rosati, F., & Della Giovampaola, C. (2020). The alpha-1,2 fucosylated tubule system of DU145 prostate cancer cells is derived from a partially fragmented Golgi complex and its formation is actin-dependent. Experimental Cell Research, 396(2), 112324. https://doi.org/10.1016/j.yexcr.2020.112324 Cite
Researchers investigated the role and mechanisms by which prostate cancer cells induce osteoclastogenesis using cultured monocytic osteoclast precursors.
[Journal of Cellular Biochemistry]
6630899 IMD28HA8 items 1 apa default asc 1
Scientists studied the cytotoxicity and genotoxicity of Mandarin peel oil on Human normal Fibroblast (HFB4) and PC3 prostate cell lines.
[Toxicology Mechanisms and Methods]
6630899 QZT5APJE items 1 apa default asc 1
Scientists observed that DLX6‐AS1 was significantly upregulated in prostate cancer (PCa) tissues and cells. Knockdown of DLX6‐AS1 inhibited PCa progression by suppressing cell proliferation and accelerating cell apoptosis.
The authors suggest that ROS-mediated genotoxic stress is involved in NaAsO2-induced cell cycle arrest, stemness enhancement and chemoresistance of prostate cancer cells in a p53-independent manner.
[Ecotoxicology and Environmental Safety]
6630899 2P9MBRAM items 1 apa default asc 1
Zhang, Z.-H., Hong, Q., Zhang, Z.-C., Xing, W.-Y., Xu, S., Tian, Q.-X., Ye, Q.-L., Wang, H., Yu, D.-X., Xie, D.-D., & Xu, D.-X. (2021). ROS-mediated genotoxic stress is involved in NaAsO2-induced cell cycle arrest, stemness enhancement and chemoresistance of prostate cancer cells in a p53-independent manner. Ecotoxicology and Environmental Safety, 208, 111436. https://doi.org/10.1016/j.ecoenv.2020.111436 Cite
Investigators studied metastatic deposits of prostate cancers with isoform-specific ΔNp63 and TAp63 antibodies. They identified p63-positive cells in only 3 of 42 metastatic prostate tumors, including 2/38 “usual-type” adenocarcinomas. ΔNp63 and TAp63 isoforms were present in the nuclei of < 1% of tumor cells in these metastases.
6630899 AYUQX9I2 items 1 apa default asc 1
Researchers undertook a novel combination therapy using rAd-p53 in situ gene therapy and immunotherapy with immune checkpoint inhibitor anti-PD-1 antibody for urogenital cancers. Three mouse syngeneic tumor cell lines, TRAMP-C2 (prostate), MBT-2 (bladder) and Renca (kidney) were used.
6630899 PH5DPRPV items 1 apa default asc 1
Kunimura, N., Kitagawa, K., Sako, R., Narikiyo, K., Tominaga, S., Bautista, D. S., Xu, W., Fujisawa, M., & Shirakawa, T. (2020). Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models. Scientific Reports, 10(1), 17464. https://doi.org/10.1038/s41598-020-74660-2 Cite
Th authors summarize current knowledge of the main gene fusions in genitourinary malignancies, discuss their growing importance in the understanding of the biology of tumours, and highlight their potential use as targets for precision medicine approaches.
[Nature Reviews Urology]
6630899 WLCEHX9B items 1 apa default asc 1
Clinical Laserthermia Systems and Otto-von-Guericke-University Magdeburg Medical faculty are entering into an agreement regarding an Investigator Initiated Trial targeting MRI-Ultrasound fusion guided focal laser ablation treatment of prostate cancer.
[Clinical Laserthermia Systems AB (publ)]
6630899 nan items 1 apa default asc 1